S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Home
Investing
Stocks
USA
NASDAQ
Dianthus Therapeutics Inc (DNTH)
Dianthus Therapeutics Inc (DNTH) Options

Dianthus Therapeutics Inc (DNTH)

86.03

3.54

( 4.29% )

Updated: 09:17:45

Dianthus Therapeutics Inc (DNTH) Options

DNTH Options Flow

Calls

Strike	Bid Price	Ask Price	Last Price	Midpoint	Change	Change %	Volume	OPEN INT	Last Trade
45.00	39.40	43.50	0.00	41.45	0.00	0.00 %	0	0	-
50.00	34.40	38.50	0.00	36.45	0.00	0.00 %	0	0	-
55.00	29.30	33.50	17.80	31.40	0.00	0.00 %	0	5	-
60.00	24.40	28.50	20.00	26.45	0.00	0.00 %	0	0	-
65.00	19.30	23.50	0.00	21.40	0.00	0.00 %	0	0	-
70.00	15.00	18.50	12.00	16.75	0.00	0.00 %	0	30	-
75.00	10.40	14.50	10.55	12.45	0.00	0.00 %	0	2	-
80.00	7.00	10.60	5.20	8.80	0.00	0.00 %	0	20	-
85.00	4.40	6.70	1.40	5.55	0.00	0.00 %	0	0	-
90.00	1.50	4.90	3.83	3.20	0.00	0.00 %	0	2	-
95.00	0.10	4.90	2.50	2.50	0.00	0.00 %	0	2	-
100.00	1.50	3.00	0.00	2.25	0.00	0.00 %	0	0	-
105.00	0.40	4.50	0.00	2.45	0.00	0.00 %	0	0	-
110.00	0.35	4.90	0.00	2.625	0.00	0.00 %	0	0	-
115.00	0.05	4.90	2.70	2.475	0.00	0.00 %	0	1	-
120.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
125.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
130.00	0.00	5.00	0.00	0.00	0.00	0.00 %	0	0	-

Professional-Grade Tools, for Individual Investors.

Premium

Puts

Strike	Bid Price	Ask Price	Last Price	Midpoint	Change	Change %	Volume	OPEN INT	Last Trade
45.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
50.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
55.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
60.00	0.00	4.90	0.80	0.80	0.00	0.00 %	0	0	-
65.00	0.05	4.90	2.45	2.475	0.00	0.00 %	0	11	-
70.00	0.30	4.90	2.62	2.60	0.00	0.00 %	0	10	-
75.00	0.10	4.90	2.60	2.50	0.00	0.00 %	0	8	-
80.00	0.50	4.90	5.90	2.70	0.00	0.00 %	0	1	-
85.00	3.00	6.50	6.81	4.75	0.00	0.00 %	0	2	-
90.00	5.50	10.00	0.00	7.75	0.00	0.00 %	0	0	-
95.00	8.50	13.20	0.00	10.85	0.00	0.00 %	0	0	-
100.00	12.50	17.30	0.00	14.90	0.00	0.00 %	0	0	-
105.00	17.00	21.80	0.00	19.40	0.00	0.00 %	0	0	-
110.00	22.00	26.80	0.00	24.40	0.00	0.00 %	0	0	-
115.00	27.00	31.80	0.00	29.40	0.00	0.00 %	0	0	-
120.00	32.00	36.10	0.00	34.05	0.00	0.00 %	0	0	-
125.00	37.00	41.10	0.00	39.05	0.00	0.00 %	0	0	-
130.00	42.00	46.90	0.00	44.45	0.00	0.00 %	0	0	-

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
OPIOffice Properties Income Trust	US$ 17.25 (8,525.00%)	6.84k
NXTSNexentis Techgnologies Inc	US$ 19.91 (291.93%)	35.72M
EHGOEshallgo Inc	US$ 4.55 (152.78%)	48.35M
TNONTenon Medical Inc	US$ 0.712801 (103.66%)	155.94M
ADTXAditxt Inc	US$ 0.018 (80.00%)	1.69B
AIXIXIAO-I Corporation	US$ 2.8852 (-53.91%)	618.46k
TOIIWOncology Institute Inc	US$ 0.03 (-49.92%)	3
LICNLichen International Ltd	US$ 1.45 (-33.18%)	223.61k
AEMDAethlon Medical Inc	US$ 1.3401 (-29.10%)	409.33k
INLFINLIF Limited	US$ 0.1126 (-28.10%)	150.94M
ADTXAditxt Inc	US$ 0.018 (80.00%)	1.69B
GDCGD Culture Group Ltd	US$ 0.0194 (7.18%)	824.39M
TNONTenon Medical Inc	US$ 0.712801 (103.66%)	155.94M
INLFINLIF Limited	US$ 0.1126 (-28.10%)	150.94M
SKYQSky Quarry Inc	US$ 1.51 (29.06%)	70.2M

iHub News

iHub News 3 months ago

Dianthus Therapeutics shares jump 25% after encouraging clinical trial updateMarch 9, 2026 10:15 AM
IH Market News
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported a fourth-quarter loss of $1.43 per share on Monday, while revenue totaled $280 thousand for the quarter ended December 31, 2025.Shares of the biotechnology company surged 25.05% in pre-market trading following the announcement.The company revealed it had reached an early GO decision in its Phase 3 CAPTIVATE trial evaluating claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The milestone was achieved after the study recorded 20 confirmed responders, with fewer than 40 of the planned participants completing the open-label Part A stage.The early GO determination came ahead of the previously expected second-quarter 2026 timeline and was based on trial criteria requiring a response rate of at least 50%. Dianthus said it expects to release guidance for the CAPTIVATE Part B top-line results by the end of 2026.“It is truly exciting to be part of a company developing potential best-in-disease therapies for patients suffering from severe autoimmune diseases,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics.For the full year 2025, Dianthus reported a net loss of $162.3 million, or $4.20 per share, compared with a net loss of $85.0 million, or $2.55 per share, in 2024.Research and development expenses rose to $145.6 million from $83.1 million year over year, primarily due to higher clinical trial costs and upfront milestone payments related to DNTH212.As of December 31, 2025, the company held $514.4 million in cash, cash equivalents and investments, which it expects will fund operations through 2028.Dianthus also plans to launch a Phase 3 registrational study of claseprubart in generalized Myasthenia Gravis in mid-2026, with top-line results anticipated in the second half of 2028.Dianthus Therapeutics stock price

Original: Dianthus Therapeutics shares jump 25% after encouraging clinical trial update

Monksdream

Monksdream 2 years ago

DNTH moving sideways

Monksdream

Monksdream 2 years ago

Dianthus Therapeutics

Amundi Japan Topix Ii Uc...

1.125% until 01/15/2032 ...

Ottakringer Getraenke

OMX Baltic Consumer Prod...

Twist Bioscience

Paramount Global

Ci North American Divide...

Flt Rte Nts 28/04/26

Tokyo Electric Power (PK)

Xtrackers MSCI Indonesia...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN

Already have an account? Sign in

Don't have an account? Sign up

By registering, I confirm I have read, understand, and agree to ADVFN's Terms and Conditions and that I am a private investor.